Fiche publication
Date publication
février 2026
Journal
Urologic oncology
Auteurs
Membres identifiés du Cancéropôle Est :
Dr BARTHELEMY Philippe
Tous les auteurs :
Moinard-Butot F, Barbe-Richaud JB, Baudry E, Pierard L, Amrane K, Maillet D, Barthélémy P
Lien Pubmed
Résumé
The treatment landscape for metastatic urothelial carcinoma (mUC) has rapidly evolved with immune checkpoint inhibitors (ICI), FGFR-targeted therapies, antibody-drug conjugates, and more recently first-line enfortumab vedotin (EV) plus pembrolizumab. In many countries, this combination is not yet available, and the standard of care (SOC) remains platinum-based chemotherapy (PBC) followed by ICI. Real-world data on treatment sequencing and attrition across therapy lines in unselected populations are limited.
Mots clés
Enfortumab vedotin, Immune checkpoint inhibitors, Metastatic bladder cancer, Real-world evidence, Treatment sequence
Référence
Urol Oncol. 2026 02 28;44(5):111036
